Are You at Increased Risk for Opioid Addiction?

Opioid addiction can impact anyone, but some people are at higher risk than others. Are you one of them? If your doctor is considering prescribing opioids to treat your acute pain (pain expected to last less than 30 days), AvertD can help you make more informed decisions by better understanding your genetic risk for opioid addiction before a prescription is written.

Are You at Increased Risk for Opioid Addiction?

Opioid addiction can impact anyone, but some people are at higher risk than others. Are you one of them? If your doctor is considering prescribing opioids to treat your acute pain (pain expected to last less than 30 days), AvertD can help you make more informed decisions by better understanding your genetic risk for opioid addiction before a prescription is written.

providers.affordable

Know Your Genetic Risk
for Opioid Use Disorder

Opioid medications are effective for treating acute pain―pain expected to last less than 30 days―but they also come with a risk of addiction. For some people, that risk is higher than others. Who is at increased risk? Some of the answer is found in our DNA.

In fact, the genes you carry are an important factor that influences whether you are at increased risk for opioid addiction (also called Opioid Use Disorder, or OUD).1 Now, thanks to AvertD™, patients and their healthcare providers have a way to identify if they may be at increased genetic risk for OUD before a first prescription is written.

AvertD Opioid Test

Make More Informed
Decisions with AvertD

AvertD is a simple genetic test that requires only a painless cheek swab. It analyzes DNA markers associated with opioid addiction and tells you if your genetic risk for addiction is high or low. Having this personalized risk information allows you and your doctor to make more informed decisions about whether the use of prescription oral opioids to treat acute pain is appropriate for you.

NOTE: Because genetics are only one factor in understanding the risk of developing OUD from using oral opioids, AvertD test results should be used in conjunction with a complete clinical evaluation to determine the appropriateness of oral opioids in a pain management plan.

Make More Informed
Decisions with AvertD

AvertD is a simple genetic test that requires only a painless cheek swab. It analyzes DNA markers associated with opioid addiction and tells you if your genetic risk for addiction is high or low. Having this personalized risk information allows you and your doctor to make more informed decisions about whether the use of prescription oral opioids to treat acute pain is appropriate for you.

NOTE: Because genetics are only one factor in understanding the risk of developing OUD from using oral opioids, AvertD test results should be used in conjunction with a complete clinical evaluation to determine the appropriateness of oral opioids in a pain management plan.

AvertD Opioid Test

AvertD is Simple
& Easy to Use

Easy

01

When a first prescription for oral opioids to treat acute pain is being considered, ask your healthcare provider to order the AvertD test.

Rapid

02

Your provider will receive your test results via a secure online portal after your sample is received and processed at our CAP-accredited and CLIA-certified lab.

Clear

03

You and your healthcare provider will review your test results, discuss your pain management options, and create a plan together.

Find Out If Prescription Opioids
Are Appropriate for You

If you are identified as having a High Genetic Risk, you and your doctor may wish to explore alternative pain management options in order to minimize or avoid use of oral opioids. It’s important to note that a High Genetic Risk result does not mean you have or will develop OUD. However, it does mean your risk of developing OUD is ~16 times higher than those with a Low Genetic Risk.2

If you are identified as having a Low Genetic Risk, you and your doctor should still follow existing medical guidelines to ensure safe and effective opioid prescribing. It’s important to note that a Low Genetic Risk result does not mean you do not have or will not develop OUD. However, your risk of developing OUD is ~16 times lower than those with a High Genetic Risk. 2

Affordable

What AvertD Testing Costs

Our goal is to offer the lowest cost option available to you. We are working diligently to ensure AvertD is covered by most insurance companies. Depending on your insurance, your maximum out-of-pocket cost may vary. If coverage is denied or only part of the test is covered, SOLVD Health may appeal the decision on your behalf. Please check with your insurance company to determine coverage. If your insurance does not pay for the test, you will be billed directly for $199.

Privacy-Trust

Your Privacy is Important

We respect your privacy and appreciate the trust you have placed in us. Our lab is CAP-accredited and CLIA-certified and follows stringent medical privacy policies and practices. We adhere to the safe and secure storage of all personal health information in a way that is fully compliant with the federal government regulations of the Health Information Portability and Accountability Act (HIPAA).

Request the AvertD Test

If you’re interested in the AvertD test, let your healthcare provider know. The test results can be used by you and your provider to decide whether opioid pain medications are an appropriate option for treating your acute pain. If they are not, you and your provider can explore other options.

Fill out our form with your provider’s contact information and we’ll contact them with information about the AvertD test. You can also download this letter, print it, and give it to your doctor at your next appointment.


1Bevilacqua L, Goldman D. Genes and addictions. Clin Pharmacol Ther. 2009; 85(4):359–361. doi:10.1038/clpt.2009.6
2Donaldson K, Cardamone D, Genovese M, Garbely J, Demers L. Clinical Performance of a Gene-Based Machine Learning Classifier in Assessing Risk of Developing OUD in Subjects Taking Oral Opioids: A Prospective Observational Study. Ann Clin Lab Sci July-August 2021 vol. 51 no. 4 451-460